Last updated: August 1, 2026
Sodium iodide I-123 is an FDA-regulated diagnostic radiopharmaceutical used primarily for thyroid uptake measurement and thyroid imaging. Its commercial outlook is stable rather than high-growth. Demand is tied to nuclear medicine capacity, thyroid diagnostic volumes, cyclotron supply and radiopharmacy logistics. The product has limited conventional patent exposure, no biosimilar pathway and little evidence of an active late-stage clinical development program for the sodium iodide I-123 molecule itself.
What is sodium iodide I-123 used for?
Sodium iodide I-123 delivers radioactive iodine to thyroid tissue through the same biological pathway as stable iodide. It emits gamma radiation suitable for planar scintigraphy and SPECT imaging and has a physical half-life of approximately 13.2 hours. Its principal photon energy is about 159 keV, which supports gamma-camera imaging with lower radiation exposure than I-131 in many diagnostic settings (U.S. Food and Drug Administration [FDA], 2024a).
The main clinical uses are:
- Thyroid uptake measurement.
- Thyroid scintigraphy.
- Evaluation of hyperthyroidism.
- Assessment of thyroid nodules and functional thyroid tissue.
- Localization of functioning thyroid tissue in selected thyroid cancer evaluations.
- Preoperative or treatment-planning support in nuclear medicine.
Sodium iodide I-123 is a diagnostic agent. It is not the same product as sodium iodide I-131, which is used for radioactive iodine therapy and ablation.
How does sodium iodide I-123 differ from I-131?
| Attribute |
Sodium iodide I-123 |
Sodium iodide I-131 |
| Primary use |
Diagnostic imaging and uptake testing |
Therapy and selected diagnostic uses |
| Physical half-life |
Approximately 13.2 hours |
Approximately 8 days |
| Main radiation |
Gamma radiation |
Beta and gamma radiation |
| Patient radiation burden |
Generally lower for diagnostic thyroid imaging |
Higher, with therapeutic tissue destruction |
| Supply model |
Cyclotron production and rapid distribution |
Reactor or cyclotron-based production, depending on supply chain |
| Commercial role |
Imaging agent |
Therapeutic radiopharmaceutical |
| Biosimilar pathway |
None |
None |
I-123 is generally preferred for diagnostic thyroid imaging when available because its radiation profile is better suited to imaging than I-131. The choice can change when supply, cost, imaging capacity or clinical protocol considerations favor other agents.
What is the current FDA status of sodium iodide I-123?
Sodium iodide I-123 is an FDA-approved diagnostic radiopharmaceutical available in capsule and, depending on supplier and presentation, other administered forms. Product labeling identifies thyroid uptake and imaging as core uses. Dosage is expressed in millicuries or megabecquerels and must account for the administration time, radioactive decay and patient-specific imaging protocol (FDA, 2024a).
The product is supplied through specialized radiopharmaceutical manufacturers and nuclear pharmacies. Distribution requires:
- Radioactive-material licensing.
- Qualified production or compounding facilities.
- Radiopharmacy handling and quality controls.
- Time-sensitive transportation.
- Dose calibration at administration.
- Compliance with federal and state radiation requirements.
The FDA regulates the drug product, while the Nuclear Regulatory Commission or an agreement state regulates possession and use of radioactive material. Facilities must comply with both pharmaceutical and radiation-safety requirements (Nuclear Regulatory Commission [NRC], 2024).
What is the Orange Book status of sodium iodide I-123?
Sodium iodide I-123 has limited relevance to the traditional Orange Book patent-certification model. The product is an established diagnostic radiopharmaceutical, and the commercial market does not appear to depend on a broad portfolio of active, product-specific Orange Book patents.
The practical barriers to competition are more operational than patent-based:
- Access to I-123 production capacity.
- Cyclotron scheduling.
- Radiochemical quality control.
- Short shelf life.
- Distribution radius.
- FDA manufacturing compliance.
- State and federal radioactive-material licensing.
The absence of significant Orange Book patent protection does not eliminate market-entry barriers. It means that a competitor is more likely to compete through regulatory approval, manufacturing reliability and distribution rather than by overcoming a dominant composition-of-matter patent.
What clinical trials are evaluating sodium iodide I-123?
The clinical-trial landscape is mature and diagnostic in character. Sodium iodide I-123 has been used as an imaging agent in clinical research, but it is not generally being developed as a new molecular entity requiring a conventional Phase 1-to-Phase 3 program.
Public trial activity involving I-123 typically falls into four categories:
- Thyroid imaging and functional assessment.
- Comparative imaging against I-131, technetium-based agents or newer tracers.
- Thyroid cancer localization and recurrence evaluation.
- Research protocols involving iodine transport, thyroid physiology or SPECT imaging.
ClinicalTrials.gov records may identify I-123 as an imaging intervention or comparator, but those studies do not necessarily represent commercial development of a new sodium iodide I-123 product (National Library of Medicine, 2024).
What is the current clinical-trial outlook?
The probability of a new pivotal registration program for standard sodium iodide I-123 is low. Clinical evidence is already extensive, and the product’s clinical value is established through routine nuclear medicine use and longstanding labeling.
Future studies are more likely to focus on:
- Protocol optimization.
- Low-dose imaging.
- Pediatric thyroid imaging.
- SPECT/CT integration.
- Thyroid cancer surveillance.
- Comparative performance against PET tracers.
- Personalized uptake measurement.
- Imaging workflow and radiation reduction.
The strongest development opportunity is not a new sodium iodide molecule. It is a better delivery format, automated dispensing platform, integrated imaging protocol or combination of I-123 imaging with advanced analytics.
How large is the sodium iodide I-123 market?
Public company disclosures rarely report sodium iodide I-123 revenue separately. Suppliers typically report broader radiopharmaceutical or nuclear medicine revenue. As a result, a precise global market size for sodium iodide I-123 cannot be reliably derived from public filings.
The market is best analyzed through demand drivers:
| Market driver |
Effect on I-123 demand |
| Thyroid imaging volume |
Direct positive effect |
| Availability of cyclotron production |
Determines regional supply |
| Nuclear medicine equipment base |
Expands or limits utilization |
| PET substitution |
Negative in selected thyroid and oncology applications |
| I-131 diagnostic use |
Competitive substitute |
| SPECT/CT adoption |
Positive for higher-value imaging workflows |
| Radiopharmacy consolidation |
Can improve distribution efficiency |
| Short half-life |
Limits geographic reach and increases logistics costs |
| Reimbursement |
Influences hospital utilization and protocol selection |
I-123 remains most defensible in thyroid imaging settings where its radiation profile, uptake characteristics and image quality provide a clinical advantage over I-131. Its use is less attractive where PET imaging, ultrasound, CT or nonradioactive laboratory testing can answer the clinical question at lower cost or with greater convenience.
What companies manufacture or distribute sodium iodide I-123?
The market is supplied by radiopharmaceutical manufacturers, hospital-based radiopharmacies and regional nuclear pharmacies. Major nuclear medicine suppliers have historically included Curium, Cardinal Health, Jubilant Radiopharma, Lantheus and other regional operators, although product availability and branding vary by country and over time.
The commercial model differs from conventional pharmaceuticals:
- Manufacturing is geographically distributed.
- Products are often ordered according to scheduled imaging volume.
- Delivery occurs close to the administration date.
- Inventory cannot be held for long periods because of radioactive decay.
- Supply interruptions can shift demand to alternative imaging agents or defer procedures.
Supplier competition is therefore based on reliable production, delivery time, dose availability, regulatory compliance and hospital contracting. Brand differentiation is limited compared with conventional prescription drugs.
What manufacturing barriers protect the market?
Manufacturing and distribution barriers are material even without strong patents. A supplier must maintain validated radioactive-material operations, qualified personnel, calibrated equipment and documented release testing. The short half-life creates a narrow window between production and administration.
A production interruption can have an immediate commercial effect. Customers cannot compensate by carrying large inventories. Regional redundancy, generator or cyclotron access and transportation capability are strategic assets.
How strong is the patent estate for sodium iodide I-123?
The patent estate for standard sodium iodide I-123 is weak compared with patented small-molecule therapeutics. The isotope and basic diagnostic use are established technologies. Core patents covering the active radioactive isotope or routine thyroid-imaging use are unlikely to create long-term exclusivity comparable to a new chemical entity.
Potentially protectable areas include:
- Capsule composition.
- Stabilizers and excipients.
- Unit-dose packaging.
- Automated dispensing systems.
- Radioactive-dose calibration methods.
- Production and purification processes.
- Cyclotron target technology.
- Imaging protocols.
- Software and image-analysis methods.
- Combination diagnostic methods.
These rights generally protect a specific formulation, apparatus, process or workflow rather than sodium iodide I-123 as a whole.
Are there Paragraph IV challenges for sodium iodide I-123?
There is no broad, high-profile Paragraph IV litigation pattern associated with standard sodium iodide I-123 comparable to major branded therapeutics. A potential competitor would more likely pursue an abbreviated or established-product regulatory route, depending on the dosage form, reference product and FDA classification.
A Paragraph IV certification is relevant only when a proposed product relies on a listed reference drug with qualifying Orange Book patent information. The commercial importance of such a challenge appears limited for standard sodium iodide I-123 because market entry is constrained more by manufacturing and distribution than by a blocking patent.
When does sodium iodide I-123 lose exclusivity?
Sodium iodide I-123 does not have a single meaningful exclusivity-loss date comparable to a branded blockbuster drug. The relevant protections are fragmented:
| Protection |
Commercial relevance |
| New chemical entity exclusivity |
Generally not relevant to this established isotope |
| Orphan-drug exclusivity |
Not a central feature of standard I-123 thyroid imaging |
| Pediatric exclusivity |
Not a principal market factor |
| Formulation patents |
May affect a specific presentation |
| Manufacturing patents |
May affect production economics or supply |
| Regulatory approval |
Remains necessary for each marketed product |
| Radiation license |
Required for facility operation and distribution |
Competition can enter when it obtains regulatory approval and establishes compliant production and distribution. The absence of a single patent cliff produces gradual, capacity-driven competition instead of a sharp generic-entry event.
What generic entry risks exist for sodium iodide I-123?
Generic risk is moderate from a product-substitution perspective but low from a conventional patent-cliff perspective. Multiple suppliers can compete if they establish equivalent quality, reliable isotope supply and adequate logistics.
The main risks to incumbent suppliers are:
- A new regional producer reducing delivery costs.
- Hospital systems shifting to internal radiopharmacy production.
- Contracting pressure from large nuclear medicine networks.
- Improved access to alternative diagnostic agents.
- PET substitution in selected oncology workflows.
- Supply-chain failures that cause customers to qualify backup suppliers.
For investors and licensors, production resilience may matter more than patent duration. A supplier with limited manufacturing redundancy can lose share quickly after a reactor, cyclotron, release-testing or transportation disruption.
How does sodium iodide I-123 compare with competing thyroid imaging agents?
| Agent |
Primary role |
Key advantage |
Main limitation |
| Sodium iodide I-123 |
Thyroid uptake and imaging |
Physiologic iodine handling and favorable diagnostic radiation profile |
Short half-life and supply dependence |
| Sodium iodide I-131 |
Imaging and therapy |
Widely established; therapeutic utility |
Higher radiation burden for routine imaging |
| Technetium-99m pertechnetate |
Thyroid imaging |
Broad nuclear medicine availability |
Does not follow all iodine-handling pathways |
| F-18 FDG |
Oncology imaging |
Strong role in many cancer evaluations |
Limited specificity for normal thyroid function |
| Thyroid ultrasound |
Structural imaging |
No radiation; accessible |
Does not measure iodine uptake |
| Thyroid PET tracers |
Selected oncology applications |
High-resolution metabolic or receptor imaging |
Higher cost and narrower indications |
I-123 retains a defensible position when the clinical question concerns thyroid physiology rather than anatomy alone. Ultrasound remains the main competitor for structural thyroid evaluation. PET is a stronger competitor in selected thyroid cancer and metastatic-disease settings.
What is the projected market outlook for sodium iodide I-123?
The base-case outlook is stable to modest growth over the next five years. A reasonable directional projection is:
| Scenario |
Market direction |
Main assumptions |
| Base case |
Low-single-digit annual growth |
Stable thyroid imaging demand, modest SPECT/CT expansion and reliable supply |
| Upside case |
Mid-single-digit annual growth |
Increased thyroid cancer surveillance, improved regional production and broader nuclear medicine access |
| Downside case |
Flat to low-single-digit decline |
PET substitution, reduced nuclear medicine utilization, reimbursement pressure or supply interruptions |
The market is unlikely to experience blockbuster-style expansion. Growth will depend on procedure volume, hospital capacity and access to isotope production. The highest-value opportunities are regional manufacturing, automated unit-dose delivery, supply redundancy and workflow integration rather than novel clinical claims.
What litigation and licensing issues affect sodium iodide I-123?
There is no widely recognized, market-defining patent litigation campaign centered on standard sodium iodide I-123. Licensing activity is more likely to involve:
- Cyclotron or reactor capacity.
- Radiopharmacy distribution agreements.
- Hospital supply contracts.
- Automated dispensing technology.
- Manufacturing know-how.
- Imaging software.
- Regional commercialization rights.
A licensing transaction involving I-123 would be commercially stronger if it secured production capacity, reduced delivery radius or integrated the product into a broader nuclear medicine portfolio. A license covering only the isotope or routine thyroid imaging indication would have limited strategic value unless it included proprietary manufacturing or distribution rights.
Key Takeaways
- Sodium iodide I-123 is an established diagnostic radiopharmaceutical for thyroid uptake and imaging.
- Its physical half-life is approximately 13.2 hours, creating major logistics and supply requirements.
- Clinical trials are mainly investigator-led imaging or protocol studies, not conventional drug-development programs.
- There is no major active patent cliff or widely reported Paragraph IV litigation pattern.
- The patent estate is more relevant to formulations, production, packaging, dispensing and imaging systems than to the isotope itself.
- Market growth is likely to remain stable or modest, with regional differences driven by cyclotron access and nuclear medicine infrastructure.
- PET, ultrasound, I-131 and technetium-based imaging are the principal competitive alternatives.
- Manufacturing reliability, regulatory compliance and distribution are stronger commercial barriers than composition-of-matter patents.
- Biosimilar risk is not applicable because sodium iodide I-123 is a radioactive small-molecule diagnostic product, not a biologic.
- The most attractive commercial opportunities involve supply-chain control, radiopharmacy automation and integrated diagnostic workflows.
FAQs
Is sodium iodide I-123 a therapeutic radiopharmaceutical?
No. Sodium iodide I-123 is primarily a diagnostic radiopharmaceutical. Sodium iodide I-131 is the iodine isotope more commonly associated with radioactive iodine therapy.
Can sodium iodide I-123 be substituted with technetium-99m?
In some thyroid imaging protocols, technetium-99m pertechnetate can provide useful thyroid images. It does not replicate all aspects of iodide transport and organification, so substitution depends on the clinical question.
Does sodium iodide I-123 require a special radioactive-material license?
Yes. Facilities handling I-123 must comply with applicable federal or state radioactive-material licensing requirements in addition to FDA drug and manufacturing rules.
Is sodium iodide I-123 protected by a composition-of-matter patent?
The established isotope and standard diagnostic use are not generally protected by a current blockbuster-style composition-of-matter patent. Specific formulations, production methods, devices and software may have separate intellectual-property protection.
What is the main investment risk for sodium iodide I-123 suppliers?
The principal risks are isotope production disruption, short shelf life, transportation failure, limited cyclotron capacity, reimbursement pressure and substitution by ultrasound, PET or other imaging approaches.
References
-
National Library of Medicine. (2024). ClinicalTrials.gov. U.S. National Library of Medicine. https://clinicaltrials.gov/
-
Nuclear Regulatory Commission. (2024). Medical use of radioactive materials. U.S. Nuclear Regulatory Commission. https://www.nrc.gov/materials/miau/med-use.html
-
Society of Nuclear Medicine and Molecular Imaging. (2023). Procedure standard for thyroid scintigraphy and uptake. SNMMI. https://www.snmmi.org/
-
U.S. Food and Drug Administration. (2024a). Sodium iodide I-123 capsule prescribing information. FDA. https://www.accessdata.fda.gov/
-
U.S. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
